Leflunomide for inflammatory arthritis in end-stage renal disease on peritoneal dialysis: A pharmacokinetic and pharmacogenetic study

Annals of Pharmacotherapy

Volumn 47, Issue 3, 2013, Pages

  Russo, Paul A J ^a,b   Wiese, Michael D ^c   Smith, Malcolm D ^d   Ahern, Michael J ^d   Barbara, Jeffrey A ^d   Shanahan, E Michael ^d  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 2C19; LEFLUNOMIDE; PREDNISOLONE; TERIFLUNOMIDE;

AGED; ARTICLE; CASE REPORT; DIALYSATE; DISABILITY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; GENOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MALE; PATIENT MONITORING; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SUDDEN DEATH; TANDEM MASS SPECTROMETRY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARYL HYDROCARBON HYDROXYLASES; ATP-BINDING CASSETTE TRANSPORTERS; HUMANS; ISOXAZOLES; KIDNEY FAILURE, CHRONIC; MALE; NEOPLASM PROTEINS; PERITONEAL DIALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84875155501     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R542     Document Type: Article

References (25)

1. Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother 2002;36:75-7. doi: 10.1345/aph.1A127
2. Iwamoto M, Homma S, Asano Y, Minota S. Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand J Rheumatol 2005;34:410-1.
3. Product information. Arava (leflunomide). Bridgewater, NJ: Sanofi-Aventis. www.sanofi.com.au/products/aus_pi_arava.pdf (accessed 2011 Dec 29).
4. Kalgutkar AS, Nguyen HT, Vaz AD, et al. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab Dispos 2003;31:1240-50. doi: 10.1124/dmd.31.10.1240
5. Rozman B. Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 2002;41:421-30.
6. Kis E, Nagy T, Jani M, et al. Leflunomide and its metabolite a771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis 2009;68:1201-7.
7. van Roon EN, Jansen TL, van de Laar MA, et al. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:569-74. doi:10.1136/ard.2004.025205
8. Chan V, Charles BG, Tett SE. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis. Br J Clin Pharmacol 2005;60:257-64. doi: 10.1111/j.1365-2125.2005.02415.x
9. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1: 611-6.
10. Kim KA, Joo HJ, Park JY. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level. Eur J Clin Pharmacol 2011;67:129-34. doi: 10.1007/s00228-010-0916-0
11. Bohanec Grabar P, Grabnar I, Rozman B, et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-cyano3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A177 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug Metab Dispos 2009;37:2061-8. doi: 10.1124/dmd.109.027482
12. Rakhila H, Rozek T, Hopkins A, et al. Quantitation of total and free teriflunomide (A77 1726) In human plasma by LC-MS/MS. J Pharm Biomed Anal 2011;55:325-31.
13. Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002;61:567-9. doi:10.1136/ard.61.6.567
14. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8. doi: 10.1002/art.22255
15. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52:262-7.
16. Chen YJ, Chang YT, Shen JL, et al. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis and psoriatic arthritis: a nationwide cohort study. Arthritis Rheum 2011;64:1879-87. doi: 10.1002/art.34335
17. Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011;270:147-57. doi: 10.1111/j.1365-2796.2010.02310.x
18. Brown F, McDonald S, Livingston B, Dent H, Excell L. Peritoneal dialysis, 11, 13. ANZDATA Registry Report 2010. Australia and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia.
19. Yang CP, Kuo MC, Guh JY, et al. Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of the literature. Ren Fail 2006;28:95-7.
20. Karanikolas GN, Koukli EM, Katsalira A, et al. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheum 2011;38:2466-74. doi: 10.3899/jrheum.110242
21. Shahnaz S, Choksi MT, Tan IJ. Bilateral cytomegalovirus retinitis in a patient with systemic lupus erythematosus and end-stage renal disease. Mayo Clin Proc 2003;78:1412-5.
22. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000;27:2927-31.
23. Inami Y, Yamaji K, Sato M, et al. Effects of dialysis on the pharmacokinetics of salazosulfapyridine. Rheumatol Int 2011; Nov 12 (Epub ahead of print). doi: 10.1007/s00296-011-2179-1
24. Akiyama Y, Fujimaki T, Sakurai Y. Pharmacokinetics of salazosulfapyridine in a hemodialysis patient. Ryumachi 2003;43:569-76.
25. Suarez-Almazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Cochrane Database Syst Rev 2000;4:CD001461. doi: 10.1002/14651858.CD001461